

REFERENCES

1. Deterbeck FC, Rivera MP, Socinski MA, Rosenman JG. *Diagnosis and treatment of lung cancer. An evidence-based guide for the practicing clinician*. 1st ed. Philadelphia: W.B. Saunders Company; 2001.
2. Boyle P, Levin B. *World cancer report 2008*. Lyon: International Agency for Research on Cancer; 2008.
3. Berhard J, Ganz PA. Psychosocial issues in lung cancer patients (part II). *Chest*. 1991;99:480-85.
4. Deesomchok A, Dechayonbancha N, Thongprasert S. Lung cancer in Maharaj Nakorn Chiangmai Hospital: Comparison of the Clinical manifestations between the young and old age groups. *J Med Assoc Thai*. 2005;88:1236-41.
5. Douglas IS, White SR. Con-Therapeutic empiricism: the case against chemotherapy in non-small cell lung cancer. *Am J Respir Crit Care Med*. 1995;151:1288-91.
6. Martin N. Lung. In: National Cancer Institute, editor. *Cancer in Thailand: Vol IV*. Bangkok; 2007. p. 41-4.
7. Lorvidhaya V, Srisukho S. *Annual report 1999. Chiang Mai cancer register, Maharaj Nakorn Chiang Mai Hospital, Faculty of Medicine, Chiang Mai University*. 2006;22.
8. American Cancer Society. *Cancer facts and figure*. Atlanta: American cancer society; 2004.

9. Corner J, Hopkinson J, Fitzsimmons D, et al. Is late diagnosis of lung cancer inevitable? Interview study of patients' recollections of symptoms before diagnosis. *Thorax*. 2005;60:314-19.
10. Welch HG, Schwartz LM, Woloshin S. Are increasing 5 year survivor rates evidence of success against cancer? *JAMA*. 2000;283:2975-78.
11. Martini N. Operable lung cancer. *CA Cancer J Clin*. 1993;43:201-14.
12. Cooper S, Spiro SG. Small cell lung cancer: Treatment review. *Respirology*. 2006;11:241-48.
13. Socinski MA. Cytotoxic chemotherapy in advanced non-small cell lung cancer. *Clin Cancer Res*. 2004;10(12):4210s-4s.
14. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide and cisplatin in unresectable non small cell lung cancer: Effects on survival and quality of life. *J Clin Oncol*. 1999;17:3188-94.
15. Fallowfield LJ, Harper P. Health-related quality of life in patients undergoing drug therapy for advanced non-small cell lung cancer. *Lung Cancer*. 2005;48:365-77.
16. Mohan A, Singh P, Kumar S, et al. Effect of change in symptoms, respiratory status, nutritional profile and quality of life on response to treatment for advanced non-small cell lung cancer. *Asian Pacific J Cancer Prev*. 2008;9:557-62.
17. Paesmans M. Benefits of chemotherapy for quality of life in patients with advanced non-small cell lung cancer. *Curr Opin Oncol*. 2002;14:389-93.
18. Bircan A, Berktas B, Bayiz H, et al. Effects of chemotherapy on quality of life for patients with lung cancer. *TRJ*. 2003;4(2):61-6.
19. Fernandez C, Rosell R, Abad-Esteve A, et al. Quality of life during chemotherapy in non-small cell lung cancer patients. *Acta Oncol*. 1989;28(1):29-33.

20. Santisevee J, Pratheppawanit N, Sukprasert A. Effects of adverse events on quality of life of non-small cell lung cancer patients: preliminary study: Khon Kaen University; 2007.
21. Thongprasert S, Sanguanmitra P, Juthapan W, et al. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. *Lung Cancer*. 1999;24:17-24.
22. Bahl A, Sharma DN, Julka PK, Rath GK. Chemotherapy related toxicity in locally advanced non-small cell lung cancer. *J Cancer Res Ther*. 2006;2:14-6.
23. Chen M-L, Yu C-T, Yang C-H. Sleep disturbances and quality of life in lung cancer patients undergoing chemotherapy. *Lung Cancer*. 2008;62(3):391-400.
24. Coates AS, Abraham S, Kaye SB, et al. On the receiving end: Patient perception of the side effects of chemotherapy. *Eur J Cancer Clin*. 1983;19:203-8.
25. Glaspy J, Degos L, Dicato M, Demetri GD. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum-and non-platinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. *Oncologist*. 2002;7:126-35.
26. Griffin AM, Butow PN, Coates AS, et al. On the receiving end. V. Patient perceptions of the side effects of cancer chemotherapy in 1993. *Ann Oncol*. 1996;7:189-95.
27. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. *J Natl Cancer Inst*. 1999;91:1616-34.
28. Holzner B, Kemmler G, Greil R, et al. The impact of hemoglobin levels on fatigue and quality of life in cancer patients. *Ann Oncol*. 2002;13:965-73.

29. Kuo TT, Ma FC. Symptoms distresses and coping strategies in patients with non-small cell lung cancer. *Cancer Nursing* 2002;25:309-17.
30. Iop A, Manfredi AM, Bonura S. Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. *Ann Oncol.* 2004;15:712-20.
31. Nerenz DR, Leventhal H, Love R. Factors contributing to emotional distress during chemotherapy. *Cancer.* 1982;50:1020-27.
32. Pujol JL, Quantin X, Chakra M. Cardiorespiratory fitness in patients with advanced non-small cell lung cancer. Why is this feature important to evaluate? Can it be improved? *J Thorac Oncol.* 2009;4:565-7.
33. Smets EMA, Garssen B, Schuster-Uitterhoeve ALJ, et al. Fatigue in cancer patients. *Br J Cancer.* 1993;68:220-4.
34. Tanaka K, Akeche T, Okuyame T, et al. Impact of dyspnea, pain, and fatigue on daily life activities in ambulatory patients with advanced lung cancer. *J Pain Symptom Manage.* 2002;23(5):417-23.
35. Cutillas JR, Rodríguez EG, Viñals NB. Chemotherapy-induced pulmonary toxicity in lung cancer management. *Rev Oncologia.* 2001;4:183-95.
36. Hochster H, Wasserheit C, Speyer J. Cardiotoxicity and cardioprotection during chemotherapy. *Curr Opin Oncol.* 1995;7:304-9.
37. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. *Drug Saf.* 2000;22:263-302.
38. Pass HI, Mitchell JB, Jonhson DH, et al. *Lung cancer: principles and research.* 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2000.
39. Schimmel KJM, Richel DJ, van den Brink RBA, et al. Cardiotoxicity of cytotoxic drugs. *Cancer Treat Rev.* 2004;30:181-91.

40. Surendiran A, Balamurugan N, Student M, et al. Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study. *Indian J Pharmacol.* 2010;42(1):40-3.
41. Gopal R, Starkschall G, Tucker SL, et al. Effects of radiotherapy and chemotherapy on lung function in patients with non-small cell lung cancer. *Int J Radiat Oncol Biol Phys.* 2003;56:114-20.
42. Leo F, Solli P, Spaggiari L, et al. Respiratory function change after chemotherapy: An additional risk for postoperative respiratory complication? *Ann Thorac Surg.* 2004;77:260-5.
43. Maas KW, Van der Lee I, Bolt K, et al. Lung function changes and pulmonary complications in patients with stage III non-small cell lung cancer treated with gemcitabine/cisplatin as part of combined modality treatment. *Lung Cancer.* 2003;41:345-51.
44. Pinson P, Klastersky J. The value of lung function measurements for the assessment of chemotherapy in lung cancer patients. *Lung Cancer.* 1998;19:179-84.
45. Shin KC, Chung JH, Lee KH. Early response of cardiopulmonary exercise test in patients with locally advanced non-small cell lung cancer treated with systemic chemotherapy. *Tuberc Respir Dis.* 2002;53:369-78.
46. Takeda S, Funakoshi Y, Kadota Y, et al. Fall in diffusion capacity associated with induction therapy for lung cancer: A predictor of postoperative complication? *Annals Thoracic Surgery.* 2006;82:232-6.
47. Kasymjanova G, Correa JA, Kreisman H, et al. Prognostic value of the six-minute walk in advanced non small cell lung cancer. *J Thorac Oncol.* 2009;4:602-7.


48. Birgegard G, Aapro MS, Bokemeyer C, et al. Cancer-related anemia: pathogenesis, prevalence and treatment. *Oncology*. 2005;68:3-11.
49. Irwin ML. Physical activity interventions for cancer survivors. *Br J Sports Med*. 2009;43:32-8.
50. Mock V, Olsen M. Current management of fatigue and anemia in patients with cancer. *Semin Oncol Nurs*. 2003;19(Supplement 2):36-41.
51. Sriplung H. Projection of cancer problems. In: National Cancer Institute, editor. *Cancer in Thailand: Vol IV*. 1st ed; 2007. p. 79-84.
52. Ministry of Thailand Public Health. *Annual report of Public Health Statistics A.D.2003-2007*. Nonthaburi; 2007.
53. Statistical register unit. *Annual report. Chiang Mai: Medical statistical register unit of Maharaj Nakorn Chiang Mai hospital Faculty of medicine Chiang Mai University*. 2006.
54. Statistical register unit. *Annual report. Chiangmai: Medical statistical register unit of Maharaj Nakorn Chiang Mai hospital Faculty of medicine Chiang Mai University*. 2009.
55. Ingle RJ. Lung cancers. In: Yarbro CH, Frogge MH, Goodman M, Groenwald SL, editors. *Cancer nursing: principle and practice*. 5th ed. London: Jones and Bartlett; 2000. p. 1298-328.
56. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: Epidemiology, Risk factors, Treatment, and Survivorship. *Mayo Clinic Proceeding*. 2008;83:584-94.
57. Boffetta P. Human cancer from environmental pollutants: the epidemiological evidence. *Mutat Res*. 2006;608:157-62.

58. Mossman BT, Kamp DW, Weitzman SA. Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers. *Cancer Invest.* 1996;14:466-80.
59. Thongprasert S, Maolekulpiroj S. *Lung cancer*. Chiang Mai: Tanabankarnpim limited partnership; 1999.
60. Tamakampee K. *Textbook of lung cancer*. 1st ed. Songkhla: Chanmuangkarnpim; 2007.
61. McCorkle R, Benoliel JQ. Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. *Soc Sci Med.* 1983;17:431-8.
62. Degner LF, Sloan JA. Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. *J Pain Symptom Manage.* 1995;10(6):423-31.
63. Cooley ME. Symptoms in adults with lung cancer. A systemic research review. *J Pain Symptom Manage.* 2000;19:137-53.
64. Potter J, Higginson IJ. Pain experienced by lung cancer patients: a review of prevalence, causes and pathophysiology. *Lung Cancer.* 2004;43:247-57.
65. Kaasa S, Mastekaasa A, Thorud E, et al. Toxicity, physical function, and everyday activity reported by patients with inoperable non-small cell lung cancer in a randomized clinical trial (chemotherapy versus radiotherapy). *Acta Oncol.* 1988;27:343-9.
66. Korst RJ, Tsuchiya R. Treatment of non-small cell lung cancer: Surgery. In: Hansen HH, editor. *Textbook of lung cancer*. London: Martin Dunitz Ltd; 2000. p. 185-200.

67. Navaravong V. Surgical management of lung cancer. In: Thongprasert S, Maolekulpiroj S, editors. *Lung Cancer*. Chiang Mai: Tanabankarnpim Ltd.; 1999.
68. Reck M, Gatzemeier U. Advanced non-small cell lung cancer: historical and future perspectives. *Targ Oncol*. 2008;3:135-47.
69. Stinchcombe TE, Socinski MA. Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy. *J Thorac Oncol*. 2009;4:243-50.
70. Oncology unit. *Treatment guideline of lung cancer patients*. Chiang Mai: Oncology unit, faculty of medicine Maharaj Nakorn Chiang Mai hospital, Chiang Mai University; 2004.
71. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. *J Natl Cancer Inst*. 2000;92:205-16.
72. Hansen HH. *Textbook of Lung Cancer*. 1st ed. London: Martin Dunitz Ltd; 2000.
73. Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. *Eur J Heart Fail*. 2002;4:235-42.
74. West JB. *Pulmonary pathophysiology (The essentials)*. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2003.
75. Mohan A, Randeep G, Ashutosh KP, et al. Quality of life measures in lung cancer. *Indian J Cancer*. 2005;42:125-32.
76. Miller MR, Hankinson J, Brusasco V, et al. Standardization of spirometry. *Eur Respir J*. 2005;26:319-38.
77. American Thoracic Society. Standardization of spirometry 1994 update. *Am J Respir Crit Care Med*. 1995;152:1107-36.

78. ATS/ACCP Statement on Cardiopulmonary Exercise Testing. *Am J Respir Crit Care Med.* 2003;167(2):211-77.
79. Solway S, Brooks D, Lacasse Y, Thomas S. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. *Chest.* 2001;119:256-70.
80. Wasserman K, Hansen JE, Sue DY, et al. *Principles of exercise testing and interpretation.* 3rd ed. Philadelphia: Lippincott, Williams & Wilkins; 1999.
81. American Thoracic Society. ATS statement: Guidelines for the six-minute walk test. *Am J Respir Crit Care Med.* 2002;166:111-7.
82. Cella DF, Bonomi AE, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT) quality of life instrument. *Lung Cancer.* 1995;12:199-220.
83. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. *J Natl cancer Inst.* 1993;85:365-76.
84. Bjordal K, de Graeff A, Fayers PM, et al. A 12 country field study of the EORTC QLQ-C30 (version3.0) and the head and neck cancer specific module (The EORTC QLQ-H&N35). *Eur J Cancer.* 2000;36:213-9.
85. Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-LC13: A modular supplement to the EORTC core quality of life (QLQ-C30) for use in lung cancer clinical trials. *Eur J Cancer.* 1994;30A:635-42.
86. Hollen PJ, Gralla RJ, Kris MG, et al. Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS). *Support Care Cancer.* 1994;2:213-22.

87. Sirisinha T, Ratanatharathorn V, Jirajarus M, et al. The european organization for research and treatment of cancer quality of life questionnaire: translation and reliability study of the thai version. J Med Assoc Thai 2002;85:1210-19.
88. Silpakit C, Sirilertrakul S, Jirajarus M, et al. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30): Validation study of the Thai version. Qual Life Res. 2006;15:167-72.



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright© by Chiang Mai University
All rights reserved